Ignite Creation Date:
2025-12-25 @ 12:07 AM
Ignite Modification Date:
2025-12-25 @ 10:06 PM
Study NCT ID:
NCT04869358
Status:
COMPLETED
Last Update Posted:
2025-05-16
First Post:
2021-04-29
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-27
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-06-13
Completion Date Type:
ACTUAL
First Submit Date:
2021-04-29
First Submit QC Date:
None
Study First Post Date:
2021-05-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-06-05
Results First Submit QC Date:
None
Results First Post Date:
2024-12-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-14
Last Update Post Date:
2025-05-16
Last Update Post Date Type:
ACTUAL